Form D · Biotechnology
Eleven Biotherapeutics, Inc.
Cambridge, MA · CIK 0001485003
Offering snapshot reported Apr 5, 2018 · SEC filing
- Reported sold
- $996K Offering amount: $996K
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 21, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 5, 2018 | Initial | $996,016 | No comparison | 10 | SEC filing |
| Sep 28, 2016 | Initial | $13,525,262 | No comparison | 6 | SEC filing |
| Dec 5, 2014 | Initial | $20,000,010 | No comparison | 10 | SEC filing |
| Oct 13, 2010 | Amendment | $8,750,000 | $4,250,000vs Feb 24, 2010 | 3 | SEC filing |
| Feb 24, 2010 | Initial | $4,500,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $36.1K
- Finders' fees
- $30.9K
- Form D file number
- 021-309400
The Company agreed to pay H.C. Wainwright & Co., LLC a portion of the fees which would have otherwise been payable to Laidlaw & Company (UK) Ltd., as a finders' fee in connection with the issuance of the securities under the purchase agreement.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Laidlaw & Company (UK) Ltd. | 119037 |
Source: Form D, filed Apr 5, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Noubar B Afeyan | Director |
| David A. Berry | Director, Executive |
| Abbie C. Celniker | Director |
| Abbie C. Celniker, Ph.D. | Director |
| Paul G. Chaney | Director |
| Leslie Dan | Director |
| Arthur P. De Cillis | Executive |
| Wendy L. Dixon | Director |
| Kim C. Drapkin | Executive |
| Jay S. Duker | Director |
| Richard F. Fitzgerald | Executive |
| Eric S. Furfine | Executive |
| Barry J. Gertz | Director |
| Jane V. Henderson | Director |
| Stephen A. Hurly | Director, Executive |
| Mark Levin | Director, Executive |
| Daniel S. Lynch | Director |
| John Mc Cabe | Executive |
| Gregory D. Perry | Executive |
| Cary G. Pfeffer | Director |
| Karen L. Turbridy | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
245 First Street Suite 1800
Cambridge, MA, 02142
Cambridge, MA, 02142